Epetraborole
Small molecule
Epetraborole is one of 49 small molecule programs targeting Lung Disease. It is currently in development.
1
Indications
5
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Lung Disease
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Viagra
VViatris Specialty LLC
Approved
Kenalog
BBassett Healthcare
Approved
Neurontin
VViatris Specialty LLC
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ketalar
AAultman Health Foundation
Approved
Inomax
MMallinckrodt
Approved
Rituxan
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lung Disease2 trials
Adult Subject1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epetraborole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- AAN2 Therapeutics, Inc